Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Recognized In 2022 TSX Venture 50 Top Performing Stocks

V.THRM

Toronto, Ontario--(Newsfile Corp. - February 24, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the Company has been recognized in the 2022 TSX Venture 50 for top performing stocks, and ranked in the top three (3) for the Life Sciences sector.

The 2022 TSX Venture 50 winners were selected based on year-over-year performance across three (3) equally weighted criteria: market capitalization growth, share price appreciation and trading volume for the year ended December 31, 2021. Therma Bright joins 49 other top performing TSX Venture companies across five (5) sectors in this honor. Learn more at TSX.com/Venture50.

"Therma Bright is honored to be placed in the TSX Venture 50 for top performing stocks and ranked third in the Life Sciences category," shared Rob Fia, CEO of Therma Bright. "With a solid 2022 outlook on our growing progressive diagnostic and medical device business, which includes our smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test that is moving through the U.S. Food & Drug Administration's Emergency Use Authorization (EUA) process, our reseller partnership with DME Authority for our Venowave, Deep Vein Thrombosis Device, and our recent U.S. Patent for our TherOZap™ and InterceptCS™ technology, we're poised to not only transform innovation into wellness, but also transform these wellness solutions into profits."

Therma Bright is not making any express or implied claims that its AcuVid™ COVID-19 Rapid Antigen Saliva Test has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/3127/114679_f1439b62a4ca8aa6_001full.jpg

Venture 50, 2022

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/3127/114679_f1439b62a4ca8aa6_001full.jpg

About Therma Bright Inc.

Therma Bright, developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the U.S. FDA in 1997. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

For further information, please contact:
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us on Twitter

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation, and regulatory applications as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/114679

Tags: